How many patients with metastatic cutaneous melanoma do you see per month, on average?

When you use an immune checkpoint blockade regimen in cutaneous melanoma in the front-line or after a front-line BRAF inhibitor containing regimen, which checkpoint regimen do you use?

• Opdivo
• Keytruda
• Opdualag
• Opdivo/Yervoy

Among the cutaneous melanoma patients you treat with an initial immune checkpoint blockade regimen, what percentage are initially refractory to the regimen?

Among the cutaneous melanoma patients you treat with an initial immune checkpoint blockade regimen, what percentage initially respond to the regimen but either progress or relapse?

Among the cutaneous melanoma patients that are initially refractory to immune checkpoint blockade, what is your next-line therapeutic regimen?

• An alternative PD-1 inhibitor containing regimen (Opdivo, Opdualag, Opidvo + Yervoy, Keytruda)
• A CTLA-4 inhibitor monotherapy (Yervoy)
• Chemotherapy (e.g. dacarbazine)
• Imlygic
• Enroll in a clinical trial

Among the cutaneous melanoma patients that initially respond to immune checkpoint blockade and subsequently progress/relapse, what is your next-line therapeutic regimen?

• An alternative PD-1 inhibitor containing regimen (Opdivo, Opdualag, Opidvo + Yervoy, Keytruda)
• A CTLA-4 inhibitor monotherapy (Yervoy)
• Chemotherapy (e.g. dacarbazine)
• Imlygic
• Enroll in a clinical trial

For cutaneous melanoma patients for which you use another immune checkpoint blockade after lack of response/progression on a prior immune checkpoint regimen, what do you believe is the likely objective response rate?

For cutaneous melanoma patients that have failed a prior immune checkpoint regimen, which therapy would you prefer as a next-line therapy if all were approved and available?

• An alternative PD-1 inhibitor containing regimen (Opdivo, Opdualag, Opidvo + Yervoy, Keytruda)
• A CTLA-4 inhibitor monotherapy regimen
• Chemotherapy (e.g. dacarbazine)
• Imlygic
• TIL therapy lifileucel
• HSV therapy RP1 plus Opdivo
• Enroll in a clinical trial

For cutaneous melanoma patients that have failed a prior immune checkpoint regimen, for what percentage would you consider a TIL therapy like lifleucel?

For cutaneous melanoma patients that have failed a prior immune checkpoint regimen, for what percentage would you consider an HSV plus PD-1 combo therapy like RP1 plus Opdivo?

What is the reason you would select a patient that failed prior immune checkpoint blockade therapy to receive lifileucel TIL therapy?

• Durable clinical responses
• One and done treatment
• Ability to provide checkpoint therapies afterwards
• Something else

What is the reason you would not select a patient that failed prior immune checkpoint blockade therapy to receive lifileucel TIL therapy? 

• Safety concerns around lymphodepletion, high-dose IL-2
• Complicated logistics of therapy production complicating treatment
• Limited efficacy data, including too low response rate and/or too short duration of response, progression-free survival or overall survival
• Absence of randomized controlled data
• Something else /Specify/

What is the reason you would select a patient that failed prior immune checkpoint blockade therapy to receive RP1 plus Opdivo HSV+PD-1 therapy?

• Durable clinical responses
• Involves only limited HSV administration followed by standard Opdivo treatment
• Positive prior experiences with HSV therapies like Imlygic
• Something else

What is the reason you would not select a patient that failed prior immune checkpoint blockade therapy to receive RP1 plus Opdivo HSV+PD-1 therapy?

• Safety concerns around HSV administration
• Negative prior experiences with HSV therapies like Imlygic
• Limited efficacy data, including too low response rate and/or too short duration of response, progression-free survival or overall survival
• Absence of randomized controlled data demonstrating benefit
• Something else /Specify/